17 Years After Viagra, the Female Viagra May Finally Be Here

Flibanserin, a drug to treat low sexual desire in women.Allen Breed/AP

Get your news from a source that’s not owned and controlled by oligarchs. Sign up for the free Mother Jones Daily.


A contentious effort to introduce a sex-drive drug for women may be nearing a climax. After rejecting “the pink Viagra” (AKA flibanserin) twice in the past five years, a Federal Drug Administration advisory committee voted today that the the pill should be approved if measures are taken to reduce its potential side effects, such as low blood pressure and fainting.

The nonhormonal drug, developed by Sprout Pharmaceutical, is meant to be taken nightly. The company says it works by altering chemicals in the brain to increase a woman’s sexual desire (unlike Viagra, which increases blood flow to certain parts of the body). Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Women who took the drug in trials reported no more than one additional “sexually satisfying event” per month than women who received a placebo.

Today’s vote comes 17 years after the FDA approved Viagra, the incredibly profitable erectile dysfunction treatment. Since then, more than two dozen prescription drugs have been approved to assist with male sexual performance, but none for women.

Even the Score, a group backed by the pharmaceutical companies that developed flibanserin, says that women also suffer from sexual dysfunction and that the unwillingness to develop and approve drugs to treat it is a matter of bias. They called today’s vote a victory for gender equality. “Women with Hypoactive Sexual Desire Disorder deserve the safety and peace of mind that comes with access to FDA-approved medical treatment options, and today we write a new chapter in the fight for equity in sexual health,” Even the Score said in a statement.

But others believe that potentially profitable drugs for a dubious disorder are being pushed with little proven effectiveness. “I don’t think there is anything sexist about denying approval for drugs that don’t have an adequate risk-to-benefit ratio,” Thea Cacchioni, a professor of women’s studies at the University of Victoria in British Columbia, told the New York Times. According to Forbes, $50 million in private investment rest on flibanserin’s approval.

The FDA is expected to come to a final decision on the drug in August.

THANKS FOR READING. NOW ONE QUICK ASK...

Trump and his allies are clamping down on the press—using lawsuits, lies, intimidation, and the power of the federal government. While major media outlets cave, Mother Jones won’t back down. To help us stand strong, a generous board member just chipped in a $50,000 digital matching gift. Will you help us make the most of it?

Every dollar you give online through September 30 will be matched dollar-for-dollar.

The forces working to demolish trust in the media and the very idea of shared facts are not slowing down. If you believe in kickass, truth-telling independent journalism, now is the time to show it. Please give what you can—any amount—and know that every dollar will go twice as far.

payment methods

THANKS FOR READING. NOW ONE QUICK ASK...

Trump and his allies are clamping down on the press—using lawsuits, lies, intimidation, and the power of the federal government. While major media outlets cave, Mother Jones won’t back down. To help us stand strong, a generous board member just chipped in a $50,000 digital matching gift. Will you help us make the most of it?

Every dollar you give online through September 30 will be matched dollar-for-dollar.

The forces working to demolish trust in the media and the very idea of shared facts are not slowing down. If you believe in kickass, truth-telling independent journalism, now is the time to show it. Please give what you can—any amount—and know that every dollar will go twice as far.

payment methods

We Recommend

Latest

Sign up for our free newsletter

Subscribe to the Mother Jones Daily to have our top stories delivered directly to your inbox.

Get our award-winning magazine

Save big on a full year of investigations, ideas, and insights.

Subscribe

Support our journalism

Help Mother Jones' reporters dig deep with a tax-deductible donation.

Donate